HGG-06. Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma without H3 K27M or BRAF Mutations: A Report from the Children's Oncology Group ACNS1721 Study

BACKGROUND: The outcome for pediatric patients with high-grade glioma (HGG) remains poor. Veliparib, a potent oral PARP1/2 inhibitor, enhances the activity of radiotherapy and DNA-damaging chemotherapy. Preclinical data indicates that veliparib crosses the blood-brain-barrier and enhances the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Karajannis, Matthias, Onar-Thomas, Arzu, Baxter, Patricia, Butingan, Nina, Fuller, Christine, Gajjar, Amar, Haque, Sofia, Jabado, Nada, Lin, Tong, Lucas, John, MacDonald, Shannon, Matsushima, Celeste, Patel, Namrata, Pierson, Christopher, Springer, Linda, Stark, Eileen, Souweidane, Mark, Walsh, Michael, Zaky, Wafik, Fouladi, Maryam, Cohen, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
High Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164928/
http://dx.doi.org/10.1093/neuonc/noac079.222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164928/
http://dx.doi.org/10.1093/neuonc/noac079.222

Ejemplares similares